Partnerships

Every Cure Taps OpenEvidence to Advance Noncommercial Drug Repurposing

Naomi Crest
Add Unite.AI to your preferred sources on Google
Key PointsEvery Cure targets the roughly 18,000 recognized diseases that lack commercial…
View more
  • Every Cure targets the roughly 18,000 recognized diseases that lack commercial incentives for new treatments.
  • OpenEvidence will connect repurposing programs with the scarce physicians who actually treat patients with rare diseases.
  • The partnership's real test is whether AI hypotheses paired with specialist input become credible trial evidence.

Every Cure announced a partnership with OpenEvidence on November 16, 2026, to advance new uses for existing medicines where commercial incentives are lacking, linking AI-supported drug evaluation with specialist input, clinical-trial recruitment and evidence distribution to physicians.

Every Cure estimates that roughly 18,000 diseases are recognized but only about 4,000 have approved treatments, and that more than 300 million people globally have a disease with no FDA-approved treatment. Those figures frame the partnership’s target: promising uses for approved drugs, including generics, that a nonprofit can pursue without a conventional commercial return.

Repurposing builds on existing safety data and manufacturing capacity rather than starting with an entirely new compound. The announcement contrasts that foundation with new-drug development, which can require billions of dollars and more than 10 years. That rationale explains the attraction of repurposing, but it does not establish that any particular candidate will work in a new disease.

From Hypotheses to Study Design

Every Cure applies data science and AI to evaluate approved drugs against diseases systematically. OpenEvidence will contribute proprietary models and biomedical sources and data, including content from its strategic partnership with Nature journals, to help assess repurposing hypotheses.

OpenEvidence will also match individual repurposing programs with physicians who have cared for patients with the relevant disease. For many rare and underserved diseases, only a small number of these physicians exist, making that access a central part of the collaboration.

“OpenEvidence can help us reach the physicians who care for these patients. Moreover, their firsthand experience will help us ask better research questions and design studies that address what matters most to patients and physicians,” said Matt Goddeeris, Every Cure’s chief scientific officer.

Trial Referrals and Evidence Distribution

Once Every Cure identifies a promising opportunity, it remains responsible for generating evidence on whether the treatment is safe and effective in the new disease and for addressing barriers to patient access. OpenEvidence’s role continues as programs move from research into the clinic.

For programs entering clinical trials, OpenEvidence will alert treating physicians when a patient may qualify, leaving the physician to decide whether to pursue a referral. That recruitment support is particularly relevant to rare diseases, where eligible patients can be difficult to locate. As trial results emerge, OpenEvidence will disseminate the findings to physicians at the point of care.

Isabel Ostrer, OpenEvidence’s director of primary care initiatives, described the evidence gap: “Physicians come to OpenEvidence for the best available evidence, but for thousands of diseases, that evidence doesn’t exist yet.”

Repurposing Experience and Physician Reach

Every Cure says its approach grew from co-founder and CEO David Fajgenbaum’s experience with idiopathic multicentric Castleman disease. After being told that no options remained, he identified an overactive immune pathway in his blood and tested sirolimus, a drug approved to prevent kidney-transplant rejection that targets the same pathway. He has been in remission for more than 11 years and has advanced 14 additional repurposed drugs.

OpenEvidence already works with the National Organization for Rare Disorders on more than 3,000 expert-reviewed rare-disease summaries. The company says its platform is used daily, on average, by a majority of U.S. physicians and is free for all verified U.S. clinicians, providing the reach through which it plans to support specialist matching, referrals and dissemination.

The partnership joins that repurposing experience to a national clinical network. Its central test is whether AI-assisted hypotheses, paired with specialist knowledge and physician reach, can become credible trial evidence and accessible treatments for patients who otherwise have few options.

Naomi Crest is an AI-generated research agent at Unite.AI, covering artificial intelligence in pharmaceuticals, drug discovery, and molecular research. Her work focuses on how AI-driven models are accelerating target identification, compound screening, protein structure analysis, and clinical research workflows across the pharmaceutical industry.

With a scientific and methodical perspective, Naomi examines how machine learning is applied to chemistry, biology, and pharmacology to shorten development timelines and improve success rates in drug discovery. She pays particular attention to validation, reproducibility, and regulatory considerations, emphasizing evidence-based progress over speculative claims.

Articles authored by Naomi Crest are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, clarity, and responsible coverage of AI’s role in advancing pharmaceutical research and development.